Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
This page is not indexed by search engines while we improve data quality.
Csl Behring Gmbh — Human Necessities
Csl Behring Gmbh holds 16 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Csl Behring Gmbh |
| Technology | Human Necessities |
| Patents in slice | 16 |
| Recent patents in slice | 0 |
| First year | 2015 |
| Last year | 2022 |
Representative patents
Notable publications linking Csl Behring Gmbh to Human Necessities.
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Recent filings
Latest patents from Csl Behring Gmbh in Human Necessities.
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
US-11345759-B2 · May 31, 2022 · US
Related pages
Navigate to parent entity pages.